CCL20 is increased in the mucosa of IBD patients [16,17,18] and CCL20 and CCR6 have been identified as IBD susceptibility genes and are suggested as treatment targets in inflammatory conditions [19,20]. The gene discussed is CCL20; the disease is inflammatory bowel disease.